» Articles » PMID: 27070705

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Abstract

The immune response influences the clinical course of colorectal cancer (CRC). Analyzing the invasive margin of human CRC liver metastases, we identified a mechanism of immune cell exploitation by tumor cells. While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5. CCR5 blockade in patient-derived functional in vitro organotypic culture models showed a macrophage repolarization with anti-tumoral effects. These anti-tumoral effects were then confirmed in a phase I trial with a CCR5 antagonist in patients with liver metastases of advanced refractory CRC. Mitigation of tumor-promoting inflammation within the tumor tissue and objective tumor responses in CRC were observed.

Citing Articles

Myeloid cells: key players in tumor microenvironments.

Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .

PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.


Multiparameter diagnostic model using S100A9, CCL5 and blood biomarkers for nasopharyngeal carcinoma.

Long L, Tao Y, Yu W, Hou Q, Liang Y, Huang K Sci Rep. 2025; 15(1):7502.

PMID: 40033021 PMC: 11876657. DOI: 10.1038/s41598-025-92518-3.


Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.


Chemokine family significance and prognostic value in colorectal cancer.

Ding Y, Chen Y, Xie S, Qiu Q, Guo X, Feng Y Front Immunol. 2025; 15():1404768.

PMID: 39835121 PMC: 11743568. DOI: 10.3389/fimmu.2024.1404768.


Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.

Mora-Lagos B, Reyes M, Lobos-Gonzalez L, Del Campo M, Buchegger K, Zanella L Biol Res. 2025; 58(1):4.

PMID: 39827154 PMC: 11748569. DOI: 10.1186/s40659-024-00581-3.